Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • emc易倍官网入口Financial Results
    • Annual Reports & Regulated Information
    • emc易倍官网入口Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • emc易倍官网入口Contacts
    • Our Locations
    • emc易倍官网入口Report Side Effects
    • emc易倍官网入口Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Fran?ais  FR     EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • emc易倍官网入口Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • Brazil
    • emc易倍官网入口 Canada
    • United States
    • emc易倍官网入口 Mexico
    • Colombia
    • Australia
    • China
    • Singapore
    • South Korea
    • emc易倍官网入口 Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • emc易倍官网入口 Greece
    • Italy
    • emc易倍官网入口 Netherlands
    • Spain
    • Poland
    • emc易倍官网入口 Russia
    • Czech Republic
    • Romania
    • Hungary
    • Slovakia
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • emc易倍官网入口History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • emc易倍官网入口Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • emc易倍官网入口Rare Disease
      • emc易倍官网入口Neuroscience
    • emc易倍官网入口Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • emc易倍官网入口Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • emc易倍官网入口Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • emc易倍官网入口People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • emc易倍官网入口Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Newsroom – Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€165.90

 €-0.10 (-0.06%)

  • Media Resources
  • Annual Report
  • emc易倍官网入口 Contacts
  • emc易倍官网入口 Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-08-27 11:13:03